APPLICATION
ANDA062226
TYPE
ANDA
ORIGINAL APPROVAL
1979-11-27
LATEST ACTION
2024-05-01
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription
Products
LAROTIDPrescription
AMOXICILLIN 250MG/5ML · FOR SUSPENSION · ORAL
AMOXILPrescription
AMOXICILLIN 250MG/5ML · FOR SUSPENSION · ORAL
AMOXILPrescription
AMOXICILLIN 50MG/ML · FOR SUSPENSION · ORAL
LAROTIDPrescription
AMOXICILLIN 125MG/5ML · FOR SUSPENSION · ORAL
AMOXILPrescription
AMOXICILLIN 125MG/5ML · FOR SUSPENSION · ORAL
Approval history
2024-05-01Labeling · Supplement 40 · standardAP
2017-05-18Labeling · Supplement 39 · standardAP
2014-12-05Labeling · Supplement 35AP
2014-11-17Labeling · Supplement 37AP
2009-03-12Labeling · Supplement 34AP
2009-03-06Labeling · Supplement 33AP
2009-02-17Labeling · Supplement 32AP
2005-09-01Labeling · Supplement 31AP
2004-10-07Labeling · Supplement 30AP
2002-12-09Manufacturing (CMC) · Supplement 29AP
2001-08-22Labeling · Supplement 27AP
2001-05-31Manufacturing (CMC) · Supplement 26AP
1999-06-08Labeling · Supplement 23AP
1998-08-04Labeling · Supplement 20AP
1998-08-04Labeling · Supplement 15AP
1998-04-20Manufacturing (CMC) · Supplement 22AP
1997-09-24Labeling · Supplement 21AP
1995-05-22Labeling · Supplement 18AP
1993-04-19Labeling · Supplement 17AP
1993-03-09Manufacturing (CMC) · Supplement 14AP
1992-06-23Manufacturing (CMC) · Supplement 13AP
1992-02-11Labeling · Supplement 16AP
1989-07-24Manufacturing (CMC) · Supplement 12AP
1979-11-27OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.